Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma
Expert Review of Pharmacoeconomics & Outcomes Research · 2026
DOI: 10.1080/14737167.2026.2612985 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026. Verfasst von Tallys Feldens und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department L'EMbeDS, Institute of Management, Sant'Anna School for Advanced Studies, Pisa, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Mobilization, Heterocyclic Compounds, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 31 Literaturangaben.
Themen: Mobilisation
Abstract (Originalsprache)
BACKGROUND: Multiple myeloma (MM) is a hematologic cancer with rising incidence worldwide. Autologous stem cell transplantation (ASCT) is a key treatment for eligible patients, but mobilization failure remains a major obstacle. Plerixafor enhances stem cell mobilization, but its high costs and lack of standardized protocol prevent its widespread use. OBJECTIVE: To evaluate the cost-utility of preemptive versus rescue use of plerixafor for hematopoietic stem cell mobilization inMM patients. METHODS: A Markov model was developed using real-world data from 196 MM patients undergoing stem cell mobilization at two SãoPaulo transplant centers in Brazil. The model compared two strategies: (1) preemptive plerixafor and (2) rescue plerixafor use following mobilization failure. Transition probabilities, utilities, and costs were informed by clinical data and literature. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: The preemptive strategy led to higher rates of successful mobilization and ASCT, resulting in greater quality-adjusted life years (QALYs), but also higher costs. Still, it demonstrated favorable results compared to the rescue approach and passed the Brazilian willingness to pay thresholds of acceptability. CONCLUSION: Preemptive plerixafor passes the cost-utility guidelines to be used in MM patients in Brazil, potentially guiding policy decisions on resource allocation within the national health system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department L'EMbeDS, Institute of Management, Sant'Anna School for Advanced Studies, Pisa, Italy.
- NEIDE (International Economics and Economic Development Research Group), Federal University of Parana, Curitiba, Brazil.
- RISE, Centre for Health Technology and Services Research, Porto, Portugal.
- Bone Marrow Transplant Unit, Hospital de Transplantes Euryclides de Jesus Zerbini, Sao Paulo, Brazil.
- Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
- Departamento de Aféreses, Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.
ORCID-Profile: Tallys Feldens, Roselene Mesquita Augusto Passos, Alessandro Gonçalves Campolina, Cesar de Almeida Neto
Zitieren
APA
Feldens, T., Mesquita Augusto Passos, R., de Oliveira Martins, J., Campolina, A. G., & de Almeida Neto, C. (2026). Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2026.2612985
Vancouver
Feldens T, Mesquita Augusto Passos R, de Oliveira Martins J, Campolina AG, de Almeida Neto C. Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research. 2026. doi:10.1080/14737167.2026.2612985
BibTeX
@article{Feldens2026,
author = {Feldens, Tallys and Mesquita Augusto Passos, Roselene and de Oliveira Martins, Juliana and Campolina, Alessandro Gonçalves and de Almeida Neto, Cesar},
title = {Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
doi = {10.1080/14737167.2026.2612985}
}
EUVIMED